Yonhap Infomax NewsSouth Korea’s Adel Inc. secures a landmark $1.04 billion global licensing deal with Sanofi for its Alzheimer’s drug candidate, marking the nation’s largest biotech tech export and underscoring investor confidence in Adel’s neurodegenerative disease research.
#YonhapInfomax
#AdelInc #Sanofi #AlzheimersDrug #LicensingDeal #StonebridgeVentures
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95764
#YonhapInfomax
#AdelInc #Sanofi #AlzheimersDrug #LicensingDeal #StonebridgeVentures
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95764
Stonebridge Ventures-Backed Adel Hits $1.04 Billion Licensing Jackpot with Global Tech Export
South Korea’s Adel Inc. secures a landmark $1.04 billion global licensing deal with Sanofi for its Alzheimer’s drug candidate, marking the nation’s largest biotech tech export and underscoring investor confidence in Adel’s neurodegenerative disease research.